Abbott Laboratories (NYSE:ABT) currently trades at $105.70, while the Street’s consensus price target sits at $118.42, implying roughly 12% of upside. Barclays analyst Matt Miksic carries the highest active target at $143, translating to about 35% in gains from here. Abbott is a diversified healthcare giant with a market cap near $182.9 billion, operating across ... Abbott Laboratories Lost 16% This Year: One Analyst Sees 35% Gains for the Healthcare Giant